X4 Pharmaceuticals Management
Management criteria checks 3/4
X4 Pharmaceuticals' CEO is Paula Ragan, appointed in Jul 2014, has a tenure of 10.33 years. total yearly compensation is $2.04M, comprised of 30.3% salary and 69.7% bonuses, including company stock and options. directly owns 0.58% of the company’s shares, worth $366.16K. The average tenure of the management team and the board of directors is 3.6 years and 5.7 years respectively.
Key information
Paula Ragan
Chief executive officer
US$2.0m
Total compensation
| CEO salary percentage | 30.3% |
| CEO tenure | 10.3yrs |
| CEO ownership | 0.6% |
| Management average tenure | 3.6yrs |
| Board average tenure | 5.7yrs |
Recent management updates
Recent updates
X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data
Jul 02Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?
Mar 26
Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?
Apr 19Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?
Oct 07X4 Pharmaceuticals: Upcoming Catalysts
Sep 19X4 Pharma to focus resources on lead drug candidate, cut workforce by about 20%
Jul 20X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended
Jul 01X4 Pharma: Late Stage Nanocap Targeting Rare Diseases
Aug 03Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?
Jun 22X4 Pharmaceuticals EPS misses by $0.44
May 06How Many X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Do Institutions Own?
Mar 16X4 Pharmaceuticals EPS misses by $0.12
Nov 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$17m |
| Jun 30 2024 | n/a | n/a | US$18m |
| Mar 31 2024 | n/a | n/a | -US$129m |
| Dec 31 2023 | US$2m | US$620k | -US$101m |
| Sep 30 2023 | n/a | n/a | -US$111m |
| Jun 30 2023 | n/a | n/a | -US$131m |
| Mar 31 2023 | n/a | n/a | -US$96m |
| Dec 31 2022 | US$4m | US$583k | -US$96m |
| Sep 30 2022 | n/a | n/a | -US$103m |
| Jun 30 2022 | n/a | n/a | -US$102m |
| Mar 31 2022 | n/a | n/a | -US$100m |
| Dec 31 2021 | US$2m | US$562k | -US$103m |
| Sep 30 2021 | n/a | n/a | -US$85m |
| Jun 30 2021 | n/a | n/a | -US$82m |
| Mar 31 2021 | n/a | n/a | -US$78m |
| Dec 31 2020 | US$3m | US$543k | -US$62m |
| Sep 30 2020 | n/a | n/a | -US$55m |
| Jun 30 2020 | n/a | n/a | -US$55m |
| Mar 31 2020 | n/a | n/a | -US$53m |
| Dec 31 2019 | US$2m | US$492k | -US$53m |
| Sep 30 2019 | n/a | n/a | -US$55m |
| Jun 30 2019 | n/a | n/a | -US$46m |
| Mar 31 2019 | n/a | n/a | -US$40m |
| Dec 31 2018 | US$921k | US$380k | -US$36m |
Compensation vs Market: Paula's total compensation ($USD2.04M) is above average for companies of similar size in the US market ($USD652.28K).
Compensation vs Earnings: Paula's compensation has been consistent with company performance over the past year.
CEO
Paula Ragan (54 yo)
10.3yrs
Tenure
US$2,044,761
Compensation
Dr. Paula Ragan, Ph D., is Member of Advisory Board of Tippingpoint Biosciences, Inc. Dr. Ragan serves as an Independent Director of CAMP4 Therapeutics Corporation since May 2019. She is a Founder of X4 Ph...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 10.3yrs | US$2.04m | 0.58% $ 366.2k | |
| CFO, Treasurer & Corporate Secretary | 6.2yrs | US$1.15m | no data | |
| Chief Medical Officer | 1.3yrs | US$1.64m | no data | |
| Founder | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Founder & Member of Corporate Advisory Board | no data | no data | no data | |
| Chief Operating Officer | 3.2yrs | US$1.84m | 0.27% $ 166.5k | |
| Chief Scientific Officer | 4yrs | no data | 0.23% $ 142.9k | |
| Senior Vice President of Clinical Development and Translational Research | no data | no data | no data | |
| Chief Commercial Officer | 2yrs | no data | 0.028% $ 17.9k |
3.6yrs
Average Tenure
60yo
Average Age
Experienced Management: XFOR's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 10.3yrs | US$2.04m | 0.58% $ 366.2k | |
| Founder & Member of Corporate Advisory Board | 8.6yrs | no data | no data | |
| Independent Chairman of the Board | 6.3yrs | US$199.34k | 0.045% $ 28.2k | |
| Director | 5.7yrs | US$147.05k | 0.030% $ 19.0k | |
| Independent Director | 7.2yrs | US$166.05k | 0.030% $ 19.0k | |
| Independent Director | 4.1yrs | US$154.55k | 0.030% $ 19.0k | |
| Independent Director | 5.2yrs | US$165.05k | 0.030% $ 19.0k | |
| Member of Corporate Advisory Board | 8.6yrs | no data | no data | |
| Independent Director | 1.1yrs | US$91.83k | no data | |
| Director | 5.7yrs | US$90.08k | 0.086% $ 54.0k | |
| Independent Director | 3.1yrs | US$152.05k | 0.030% $ 19.0k |
5.7yrs
Average Tenure
62yo
Average Age
Experienced Board: XFOR's board of directors are considered experienced (5.7 years average tenure).